On July 13, Vicky Technology (920176.BJ) commenced its public subscription, with an issue price set at 22.16 yuan per share. The maximum subscription amount is 397,300 shares, and the price-to-earnings ratio is 14.99 times. The listing is on the Beijing Stock Exchange, with Guosen Securities acting as the sponsor.
According to the prospectus, Vicky Technology is an innovation-driven, specialized and sophisticated "little giant" enterprise in the cosmetics ingredients sector. It is dedicated to promoting innovative and plant-based ingredients from China to the global market, aiming to build a globally influential Chinese cosmetics ingredient brand.
The company pioneered a peptide-based skincare system centered on "active peptides," developing over ten skincare solutions targeting anti-aging, wrinkle reduction, whitening, oil control and acne treatment, hair growth, soothing and anti-sensitivity, repair, moisturizing, eye care, lip care, and stretch mark repair.
As of the signing date of the prospectus, the company possesses 22 new cosmetic ingredients approved and filed with the National Medical Products Administration, including nine innovative new ingredients. The company ranks among the top in terms of the number of approved new ingredient filings, holding the top position for the number of approved innovative new ingredient filings.
The company's self-developed Erasin0003 is the first innovative new ingredient in China with independent intellectual property rights approved by the NMPA. It is also one of the first two new ingredients to be included in the "Inventory of Existing Cosmetic Ingredients" after completing a three-year safety monitoring period.
Inclusion in this official inventory lowers the application barrier for brands, reduces product filing costs, and shortens the filing cycle. Currently, the company is leveraging these new ingredients as an opportunity to advance collaborations with internationally renowned brands such as Shiseido and Estée Lauder, with some products already included in these brands' supplier catalogs.
On the financial front, for the 2023, 2024, and 2025 fiscal years, the company achieved operating revenues of approximately 165 million yuan, 248 million yuan, and 275 million yuan, respectively. During the same periods, it recorded net profits of approximately 42.29 million yuan, 70.64 million yuan, and 90.85 million yuan, respectively.
Comments